The show is over for Aslan Pharmaceuticals (Nasdaq: ASLN), the immunology-focused biopharmaceutical company, as its financial troubles have led it to file for voluntary liquidation.
This decision follows a comprehensive review by the board of Aslan’s financial position and strategic alternatives. All employees have been dismissed.
Liquidators will be responsible for the orderly winding up of Aslan’s affairs, including seeking potential strategic alternatives for its development programs and the company’s primary assets, eblasakimab and farudodstat.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze